← Back to Clinical Trials
Recruiting Phase 3 NCT04064840

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Subfertility
Sponsor The University of Hong Kong
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 784
Sex FEMALE
Min Age 18 Years
Max Age 42 Years
Start Date 2019-09-01
Completion 2024-09-01
Interventions
IVF: Decapeptyl and hCGFET: DecapeptylIVF: hCG and normal saline

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.

Eligibility Criteria

IVF Inclusion criteria: \- Women aged \<43 years at the time of IVF treatment Exclusion criteria: * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated * Women at risk of OHSS FET Inclusion criteria: * Women aged \<43 years at the time of IVF treatment * Replacing early cleavage embryos or blastocysts after thawing * FET in natural cycles Exclusion criteria: * Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}